A study of the interaction between recombinant bactericidal permeability increasing protein (rBPI(23)) and gentamicin.
rBPI(23) is a recombinant protein based upon the N-terminal sequence of bactericidal permeability increasing protein (BPI), a protein present in the granules of polymorphonuclear leukocytes. BPI has antibacterial activity against Gram-negative organisms and potent endotoxin neutralising properties. rBPI(23) has been developed as a potential agent for use in Gram-negative sepsis and has completed phase 1 clinical trials. In this study a broth microdilution chequerboard method has been used to investigate the interaction between rBPI(23) and gentamicin, an antibiotic used in a similar clinical setting. Using organisms with a range of inherent susceptibilities to rBPI(23), additive or synergistic effects were seen which tended to be proportional to the sensitivity to rBPI(23) alone.